Cleary Gottlieb represented GlaxoSmithKline plc and GlaxoSmithKline Capital Inc., a finance subsidiary, in the offering by GlaxoSmithKline Capital Inc. of $2.5 billion of 4.850% Notes due 2013, $2.75 billion of 5.650% Notes due 2018, $2.75 billion of 6.375% Notes due 2038 and $1 billion of Floating Rate Notes due 2010. The notes, issued under a shelf registration statement and wholly and unconditionally guaranteed by GlaxoSmithKline plc, have been listed on the New York Stock Exchange. The offering closed on May 13.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.